/CRON
CRON Stock - Cronos Group Inc.
Healthcare|Drug Manufacturers - Specialty & GenericNASDAQ
$2.96-0.34%
$0.01 (-0.34%) • Dec 19
78
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.96
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).82
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.78
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.9%upside
Target: $3.43
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRON
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.93 – $2.99
TARGET (TP)$3.43
STOP LOSS$2.72
RISK/REWARD1:2.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.04
52W High$3.43
52W Low$1.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $117.61M | $87.24M | $86.75M | $64.56M | $46.72M |
| Gross Profit | $25.20M | $11.91M | $15.44M | $-17,593,000 | $-25,833,000 |
| Gross Margin | 21.4% | 13.7% | 17.8% | -27.3% | -55.3% |
| Operating Income | $-76,529,000 | $-84,800,000 | $-111,428,000 | $-291,969,000 | $-219,387,000 |
| Net Income | $41.08M | $-73,963,000 | $-168,734,000 | $-396,107,000 | $-73,137,000 |
| Net Margin | 34.9% | -84.8% | -194.5% | -613.5% | -156.5% |
| EPS | $0.11 | $-0.19 | $-0.45 | $-1.07 | $-0.21 |
Company Overview
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. It also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$3
Average Target
↑ 1.4% Upside
Now
$3
Low
$3
Average
$3
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 2nd 2022 | Bernstein | Initiation | Market Perform | $3 |
| July 28th 2022 | Canaccord Genuity | Upgrade | Buy | - |
| May 11th 2022 | CIBC | Upgrade | Sector Outperform | - |
Earnings History & Surprises
CRONBeat Rate
12%
Last 17 quarters
Avg Surprise
-113.0%
EPS vs Estimate
Beats / Misses
2/12
3 met exactly
Latest EPS
$0.07
Q4 2025
EPS Surprise History
Q1 24
-233.3%
$-0.05vs$-0.01
Q2 24
-25.0%
$-0.01vs$-0.01
Q3 24
-700.0%
$-0.02vs$-0.00
Q4 24
-300.0%
$-0.02vs$-0.01
Q1 25
0.0%
$-0.01vs$-0.01
Q2 25
+378.6%
$0.02vs$-0.01
Q3 25
-400.0%
$-0.10vs$-0.02
Q4 25
0.0%
$0.07vs$0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.01 | — | — | — |
Q4 2025 | Nov 6, 2025 | $0.07 | $0.07 | 0.0% | = MET |
Q3 2025 | Aug 7, 2025 | $-0.02 | $-0.10 | -400.0% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.01 | $0.02 | +378.6% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.01 | $-0.01 | 0.0% | = MET |
Q4 2024 | Nov 12, 2024 | $-0.01 | $-0.02 | -300.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.00 | $-0.02 | -700.0% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.01 | $-0.01 | -25.0% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.01 | $-0.05 | -233.3% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.00 | $-0.00 | -100.0% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.01 | $-0.02 | -68.8% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.04 | $-0.03 | +25.0% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.05 | $-0.14 | -180.0% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.06 | $-0.07 | -16.7% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.05 | $-0.05 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $-0.10 | $-0.36 | -260.0% | ✗ MISS |
Q1 2022 | Feb 18, 2022 | — | $0.16 | — | — |
Q3 2021 | Aug 6, 2021 | $-0.07 | $-0.09 | -28.6% | ✗ MISS |
Latest News
Marijuana stocks sell off as Trump signs executive order to reclassify cannabis
📉 NegativeDowjones•Dec 18, 2025, 09:24 PM•Also: , ,
Cannabis stocks selling off as Trump signs rescheduling order
📉 NegativeSeeking Alpha•Dec 18, 2025, 07:21 PM•Also: , ,
U.S. Centers For Medicare & Medicaid Services Administrator Says Millions Of Americans On Medicare To Become Eligible To Receive CBD As Early As April
📈 PositiveBenzinga•Dec 18, 2025, 06:59 PM•Also: , ,
Trump Order Will Direct Maintaining Restrictions On Dangerous Products; Centers For Medicare & Medicaid Services Plans To Allow Beneficiaries To Benefit From Hemp-derived Cbd Products At No Cost; Trump Order Will Not Encourage Use, But Recognizes Potential Both Therapeutic Uses And Risks Like Addiction; Marijuana Will Remain Illegal To Possess Under Federal Law; Trump Order Makes No Changes To Criminal Penalties Or Access For Recreational Use Of Marijuana
➖ NeutralBenzinga•Dec 18, 2025, 06:51 PM•Also: , ,
Trump To Sign Executive Order On Thursday Aiming To Expedite Reclassification Of Marijuana As Schedule III Substance; Trump Order Will Allow More Research Of Medical Marijuana And Cannabidiol; Trump Order Will Help U.s. To Better Understand Risks Associated With Marijuana; There Is Currently Insufficient Evidence Of Marijuana's Medical Uses; Trump Order Will Direct White House To Work With Congress To Improve Access To Hemp-Derived CBD Products
📈 PositiveBenzinga•Dec 18, 2025, 06:49 PM•Also: , ,
'Trump's Marijuana Executive Order Details Leaked Ahead Of Announcement, Including CBD And Hemp Provisions'- Marijuana Moment
📈 PositiveBenzinga•Dec 18, 2025, 05:50 PM•Also: , ,
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
📈 PositiveBenzinga•Dec 18, 2025, 12:21 PM•Also: , ,
'Trump's Marijuana Rescheduling Order Could Include Industry Banking And CBD Medicare Coverage Provisions, Sources Say;'- Marijuana Moment
📈 PositiveBenzinga•Dec 17, 2025, 05:01 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following reports suggesting President Trump will sign an executive order that will reclassify marijuana to a Schedule III drug.
📈 PositiveBenzinga•Dec 17, 2025, 02:38 PM•Also: , ,
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
📈 PositiveBenzinga•Dec 17, 2025, 01:38 PM•Also: , ,
'Trump Expected To Sign An Order Moving To Reclassify Cannabis And Open Up Medical Potential' - NBC News
📈 PositiveBenzinga•Dec 17, 2025, 09:12 AM•Also: , ,
Shares of cannabis-linked stocks are trading higher after President Donald Trump confirmed his administration is strongly considering reclassifying marijuana.
📈 PositiveBenzinga•Dec 16, 2025, 07:17 PM•Also: , ,
Liz Claman Posts On X "ALERT: Word is a @realDonaldTrump executive order to reclassify cannabis/marijuana as less dangerous, less regulated Class III substance
📈 PositiveBenzinga•Dec 15, 2025, 08:48 PM•Also: , ,
President Trump Says Considering Executive Oder To Reclassify Marijuana
➖ NeutralBenzinga•Dec 15, 2025, 08:45 PM•Also: , ,
Shares of cannabis-linked stocks are trading higher following a report suggesting that President Trump is expected to reclassify marijuana as a Schedule III drug.
📈 PositiveBenzinga•Dec 12, 2025, 01:23 PM•Also: , ,
Cronos Group shares are trading higher after the company announced an agreement to acquire CanAdelaar for up-front cash consideration of $67 million.
📈 PositiveBenzinga•Dec 9, 2025, 05:54 PM
Cronos Group Subsidiary To Acquire All Outstanding Shares Of CanAdelaar For Up-Front Consideration Of $67M Plus Cash Earnout Of 0.5x Normalized EBITDA In 2026 And 2027
📈 PositiveBenzinga•Dec 9, 2025, 12:35 PM
'Nebraska Supreme Court Hears Case Seeking To Overturn Medical Marijuana Law Approved By Voters' - Marijuana Moment
➖ NeutralBenzinga•Dec 4, 2025, 01:59 PM•Also: , ,
UPDATE: 'Medicare to Test Making CBD Treatment Available for Seniors' - Bloomberg News
📈 PositiveBenzinga•Nov 26, 2025, 05:58 PM•Also: , ,
'Marijuana Banking Bill Is 'On The Back Burner,' As Congressional Lawmakers See No Indication It'll Advance Soon' - Marijuana Moment
📉 NegativeBenzinga•Nov 25, 2025, 03:27 PM•Also: , ,
Frequently Asked Questions about CRON
What is CRON's current stock price?
Cronos Group Inc. (CRON) is currently trading at $2.96 per share. The stock has moved -0.34% today.
What is the analyst price target for CRON?
The average analyst price target for CRON is $3.43, based on 1 analyst.
What sector is Cronos Group Inc. in?
Cronos Group Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.
What is CRON's market cap?
Cronos Group Inc. has a market capitalization of $1.13 billion, making it a small-cap company.
Does CRON pay dividends?
No, Cronos Group Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMPH
Amphastar Pharmaceuticals, Inc.
$26.60
Mkt Cap: $1.2B
BBOT
BridgeBio Oncology Therapeutics Inc.
$12.52
Mkt Cap: $1.0B
COLL
Collegium Pharmaceutical, Inc.
$48.88
Mkt Cap: $1.5B
EMBC
Embecta Corp.
$11.75
Mkt Cap: $0.7B
IRMD
IRadimed Corporation
$97.19
Mkt Cap: $1.2B
NRIX
Nurix Therapeutics, Inc.
$18.52
Mkt Cap: $1.4B
PCRX
Pacira BioSciences, Inc.
$26.35
Mkt Cap: $1.2B
PHAT
Phathom Pharmaceuticals, Inc.
$17.53
Mkt Cap: $1.2B
RAPP
Rapport Therapeutics, Inc. Common Stock
$30.85
Mkt Cap: $1.1B
XNCR
Xencor, Inc.
$15.55
Mkt Cap: $1.1B
Explore stocks similar to CRON for comparison